New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
08:16 EDTLGND, MRKLigand announces $1M milestone payment triggered by FDA approval of NOXAFIL
Ligand Pharmaceuticals Incorporated (LGND) announces that it has earned a $1M milestone payment as a result of the recent U.S. Food and Drug Administration approval of Merck’s (MRK) NOXAFIL injection. This is a new Captisol-enabled formulation of NOXAFIL for intravenous use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement.
News For LGND;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
08:33 EDTMRKFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
07:41 EDTLGNDEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
April 13, 2015
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
April 10, 2015
09:15 EDTLGNDLigand management to meet with Deutsche Bank
Subscribe for More Information
09:06 EDTLGNDLigand amends Master License Agreement with Viking Therapeutics
Subscribe for More Information
April 9, 2015
09:25 EDTMRKPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
07:14 EDTMRKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use